{
    "Remission (follow up: 1 year; assessed with: DAS28 - CRP < 2.6)": {
        "No of studies": "8",
        "Study design": "randomised trials",
        "Risk of bias": "not serious",
        "Inconsistency": "not serious",
        "Indirectness": "not serious",
        "Imprecision": ["very serious", "a"],
        "Other considerations": "none",
        "Nº of patients": {
            "ABA": "48/113 (42.5%)",
            "MTX monotherapy": "52/115 (45.2%)"
        },
        "Effect": {
            "Relative (95% CI)": "RR 0.94 (0.70 to 1.26)",
            "Absolute (95% CI)": "27 fewer per 1,000 (from 136 fewer to 118 more)"
        },
        "Certainty": "⨁⨁◯◯ LOW",
        "Importance": "CRITICAL"
    },

    "Disability (follow up: 1 year; assessed with: HAQ - DI ≥ 0.3)": {
        "No of studies": "8",
        "Study design": "randomised trials",
        "Risk of bias": "not serious",
        "Inconsistency": "not serious",
        "Indirectness": "not serious",
        "Imprecision": ["very serious", "a"],
        "Other considerations": "none",
        "Nº of patients": {
            "ABA": "61/113 (54.0%)",
            "MTX monotherapy": "51/115 (44.3%)"
        },
        "Effect": {
            "Relative (95% CI)": "RR 1.22 (0.93 to 1.59)",
            "Absolute (95% CI)": "98 more per 1,000 (from 31 fewer to 262 more)"
        },
        "Certainty": "⨁⨁◯◯ LOW",
        "Importance": "IMPORTANT"
    },

    "Serious adverse events (1 year)": {
        "No of studies": "8",
        "Study design": "randomised trials",
        "Risk of bias": "not serious",
        "Inconsistency": "not serious",
        "Indirectness": "not serious",
        "Imprecision": ["very serious", "a"],
        "Other considerations": "none",
        "Nº of patients": {
            "ABA": "14/116 (12.1%)",
            "MTX monotherapy": "9/116 (7.8%)"
        },
        "Effect": {
            "Relative (95% CI)": "RR 1.56 (0.70 to 3.45)",
            "Absolute (95% CI)": "43 more per 1,000 (from 23 fewer to 190 more)"
        },
        "Certainty": "⨁⨁◯◯ LOW",
        "Importance": "IMPORTANT"
    },

    "Withdrawal due to adverse events (follow up: 1 year)": {
        "No of studies": "8",
        "Study design": "randomised trials",
        "Risk of bias": "not serious",
        "Inconsistency": "not serious",
        "Indirectness": "not serious",
        "Imprecision": ["very serious", "a"],
        "Other considerations": "none",
        "Nº of patients": {
            "ABA": "8/116 (6.9%)",
            "MTX monotherapy": "5/116 (4.3%)"
        },
        "Effect": {
            "Relative (95% CI)": "RR 1.60 (0.54 to 4.75)",
            "Absolute (95% CI)": "26 more per 1,000 (from 20 fewer to 162 more)"
        },
        "Certainty": "⨁⨁◯◯ LOW",
        "Importance": "IMPORTANT"
    },

    "Withdrawal due to lack of efficacy (follow up: 1 year)": {
        "No of studies": "8",
        "Study design": "randomised trials",
        "Risk of bias": "not serious",
        "Inconsistency": "not serious",
        "Indirectness": "not serious",
        "Imprecision": ["very serious", "a"],
        "Other considerations": "none",
        "Nº of patients": {
            "ABA": "6/116 (5.2%)",
            "MTX monotherapy": "11/116 (9.5%)"
        },
        "Effect": {
            "Relative (95% CI)": "RR 0.55 (0.21 to 1.43)",
            "Absolute (95% CI)": "43 fewer per 1,000 (from 75 fewer to 41 more)"
        },
        "Certainty": "⨁⨁◯◯ LOW",
        "Importance": "IMPORTANT"
    },

    "Death (follow up: 1 year)": {
        "No of studies": "8",
        "Study design": "randomised trials",
        "Risk of bias": "not serious",
        "Inconsistency": "not serious",
        "Indirectness": "not serious",
        "Imprecision": ["very serious", "b"],
        "Other considerations": "none",
        "Nº of patients": {
            "ABA": "0/116 (0.0%)",
            "MTX monotherapy": "0/116 (0.0%)"
        },
        "Effect": {
            "Relative (95% CI)": "not estimable",
            "Absolute (95% CI)": ""
        },
        "Certainty": "⨁⨁◯◯ LOW",
        "Importance": "IMPORTANT"
    },

    "Malignancy (follow up: 1 year)": {
        "No of studies": "8",
        "Study design": "randomised trials",
        "Risk of bias": "not serious",
        "Inconsistency": "not serious",
        "Indirectness": "not serious",
        "Imprecision": ["very serious", "b"],
        "Other considerations": "none",
        "Nº of patients": {
            "ABA": "2/116 (1.7%)",
            "MTX monotherapy": "1/116 (0.9%)"
        },
        "Effect": {
            "Relative (95% CI)": "RR 2.00 (0.18 to 21.75)",
            "Absolute (95% CI)": "9 more per 1,000 (from 7 fewer to 179 more)"
        },
        "Certainty": "⨁⨁◯◯ LOW",
        "Importance": "IMPORTANT"
    },

    "Malignancy (from SR of harms) ABA vs MTX": {
        "No of studies": "9",
        "content": "The Systematic Review RefID=1220, 2017 (RCTs=4, n=Not provided) comparing Abatacept vs Placebo + csDMARD among RA and showed that for Cancer, the result was Peto OR=1.12 (0.33, 3.81)",
        "Certainty": "-",
        "Importance": "IMPORTANT"
    }
}